Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.48 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | WNT1 | P04628 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23923854 | 1.00 | ABL1 (0.48) | ABL1DEGS1KDM4EALDH1A1ROCK2 | |
| SCHEMBL23951729 | 0.87 | TACR1 (0.55) | ABL1DEGS1TRPV1GSK3BDYRK1A | |
| SCHEMBL29900688 | 0.87 | TACR1 (0.55) | ABL1DEGS1TRPV1GSK3BDYRK1A | |
| SCHEMBL28932930 | 0.87 | TACR1 (0.55) | ABL1DEGS1TRPV1GSK3BDYRK1A | |
| SCHEMBL558873 | 0.84 | GSK3B (0.54) | ABL1ROCK2WNT1GSK3BDYRK1A | |
| SCHEMBL23951289 | 0.79 | ROCK2 (0.53) | ABL1DEGS1KDM4EALDH1A1ROCK2 | |
| SCHEMBL23951527 | 0.79 | ROCK2 (0.53) | ABL1DEGS1KDM4EALDH1A1ROCK2 | |
| SCHEMBL23951321 | 0.79 | ROCK2 (0.53) | ABL1DEGS1KDM4EALDH1A1ROCK2 | |
| SCHEMBL23951267 | 0.79 | ROCK2 (0.53) | ABL1DEGS1KDM4EALDH1A1ROCK2 | |
| SCHEMBL23951581 | 0.79 | ROCK2 (0.53) | ABL1DEGS1KDM4EALDH1A1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | ABL1 2707/4885DEGS1 4570/4885KDM4E 2961/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | ABL1 2707/4885DEGS1 4570/4885KDM4E 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.